The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZLAB | -28.92% | -75.13% | -24.27% | +22% |
| S&P | +12.65% | +91.73% | +13.89% | +169% |
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Zai Lab's shares benefited from positive clinical trial news.
The company released a phase 3 trial regarding a non-small cell lung cancer therapy.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $116.25M | 13.7% |
| Gross Profit | $69.30M | 6.1% |
| Gross Margin | 60.70% | -4.2% |
| Market Cap | $3.77B | 57.6% |
| Market Cap / Employee | $2.02M | 0.0% |
| Employees | 1.9K | -14.1% |
| Net Income | -$36.01M | 13.6% |
| EBITDA | -$48.35M | 31.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $817.15M | 14.1% |
| Accounts Receivable | $105.00M | 51.6% |
| Inventory | 67.1 | 69.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.84M | 77.3% |
| Short Term Debt | $208.52M | 74.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.74% | 8.8% |
| Return On Invested Capital | -37.41% | 6.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.28M | 20.1% |
| Operating Free Cash Flow | -$31.38M | 25.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.86 | 4.63 | 4.68 | 4.70 | 39.84% |
| Price to Sales | 6.65 | 6.69 | 9.35 | 8.93 | 70.55% |
| Price to Tangible Book Value | 4.19 | 4.96 | 5.02 | 5.07 | 41.17% |
| Enterprise Value to EBITDA | -28.24 | -31.11 | -64.38 | -65.72 | 346.84% |
| Return on Equity | -35.1% | -31.4% | -32.0% | -28.4% | -22.30% |
| Total Debt | $153.47M | $192.30M | $191.40M | $219.36M | 74.52% |
No podcast episodes available.
ZLAB earnings call for the period ending June 30, 2020.
ZLAB earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
